73 results
8-K
EX-99.2
NGNE
Neurogene Inc
4 Mar 24
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett
7:30am
with Autonomic Function Objective device to monitor breathing Classic Rett syndrome Clinical diagnosis & genetic Hand Function Physician assessment … of improvement confirmation of pathogenic MeCP2 mutation Clinical Global Impression- Communication Physician assessment of improvement Severity (CGI-S)score
8-K
EX-99.2
NGNE
Neurogene Inc
5 Jan 24
Neurogene Announces Business Update and 2024 Outlook
7:11am
assessment of improvement Communication Physician assessment of improvement Gross Motor Function Physician assessment of improvement Cohort 1 Study
8-K
EX-99.5
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
immediately prior to the closing of the merger. Based on an assessment of the Neurogene pre-funded warrants specific terms in the draft agreement
S-4/A
anowvdtr
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4/A
EX-10.35
zh1cd
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4
obn c0inrs
18 Aug 23
Registration of securities issued in business combination transactions
6:19pm
425
qwlsi2d
18 Jul 23
Business combination disclosure
8:37am
8-K
EX-2.1
dxyun2 iq
18 Jul 23
Neurogene and Neoleukin Announce Definitive Merger Agreement
8:34am